Related Experiment Video

Updated: Jul 17, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for

Volker Limmroth1, Rolf Malessa, Uwe Klaus Zettl

  • 1Dept. of Neurology, Cologne City Hospitals, University of Colognen, Ostmerheimerstr. 200, 51109, Cologne, Germany. limmrothv@kliniken-koeln.de

Journal of Neurology
|February 3, 2007
PubMed

Insights

Interferon beta (IFN beta) treatments for multiple sclerosis (MS) show similar effectiveness. Switching between different IFN beta therapies does not improve patient outcomes, with initial therapy being more beneficial than follow-up treatment.

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Interferon beta (IFN beta) preparations are primary disease-modifying therapies for relapsing multiple sclerosis (MS).
  • Previous studies suggest comparable efficacy among different IFN beta formulations.

Purpose of the Study:

  • To compare the effectiveness and tolerability of available IFN beta preparations in relapsing MS patients.
  • To evaluate the impact of initial versus follow-up therapy with IFN beta preparations.

Main Methods:

  • A large, retrospective, open-label observational cohort study (QUASIMS) involving 510 sites in Germany, Austria, and Switzerland.
  • Chart review of 4754 patients treated with one of four IFN beta preparations for at least two years.
  • Outcomes assessed included changes in Expanded Disability Status Scale (EDSS), relapse rates, and reasons for therapy change.

Main Results:

  • No significant differences in effectiveness were observed among the evaluated IFN beta preparations, whether used as initial or follow-up therapy.
  • Patients receiving IFN beta as initial therapy demonstrated consistently superior outcomes (lower relapse rates, higher relapse-free rates) compared to those on follow-up therapy.
  • Switching between IFN beta preparations did not lead to improved disease outcomes.

Conclusions:

  • Available Interferon beta preparations demonstrate similar effectiveness for treating relapsing multiple sclerosis.
  • Initiating therapy with an IFN beta preparation is more beneficial than switching between them later.
  • Patients with MS are unlikely to gain additional benefits from switching between different IFN beta therapies.

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...